Wall Street brokerages expect that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) will report sales of $29.91 million for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Deciphera Pharmaceuticals’ earnings, with estimates ranging from $25.43 million to $32.00 million. Deciphera Pharmaceuticals posted sales of $23.57 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.9%. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Deciphera Pharmaceuticals will report full-year sales of $124.09 million for the current year, with estimates ranging from $105.05 million to $134.00 million. For the next fiscal year, analysts expect that the company will post sales of $155.94 million, with estimates ranging from $127.83 million to $172.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.03. Deciphera Pharmaceuticals had a negative net margin of 279.96% and a negative return on equity of 79.96%. The business had revenue of $29.22 million for the quarter, compared to analyst estimates of $27.17 million. During the same quarter last year, the business earned ($1.06) earnings per share. The business’s revenue for the quarter was up 16.2% on a year-over-year basis.
NASDAQ DCPH opened at $9.99 on Wednesday. Deciphera Pharmaceuticals has a 12 month low of $6.51 and a 12 month high of $11.47. The firm has a market capitalization of $661.51 million, a price-to-earnings ratio of -2.04 and a beta of 1.41. The company’s 50 day moving average is $9.47.
In other news, major shareholder Brightstar Associates Llc acquired 1,478,978 shares of the firm’s stock in a transaction that occurred on Friday, April 29th. The stock was purchased at an average price of $10.00 per share, with a total value of $14,789,780.00. Following the purchase, the insider now owns 18,051,348 shares of the company’s stock, valued at approximately $180,513,480. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 3,718 shares of company stock valued at $33,648 in the last ninety days. Company insiders own 4.10% of the company’s stock.
A number of institutional investors have recently bought and sold shares of DCPH. Quadrant Capital Group LLC boosted its stake in Deciphera Pharmaceuticals by 13,182.8% in the 4th quarter. Quadrant Capital Group LLC now owns 3,852 shares of the company’s stock worth $38,000 after purchasing an additional 3,823 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at $53,000. Denali Advisors LLC acquired a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter valued at $58,000. Los Angeles Capital Management LLC acquired a new stake in shares of Deciphera Pharmaceuticals during the 1st quarter valued at $98,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Deciphera Pharmaceuticals by 255.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,046 shares of the company’s stock valued at $137,000 after buying an additional 10,091 shares during the period. 87.97% of the stock is owned by hedge funds and other institutional investors.
Deciphera Pharmaceuticals Company Profile (Get Rating)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- 3 Online Education Stocks Investors Should Study
- XPO Logistics Is A Logical Choice For Investors
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.